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1Elevated rates of vascular smooth muscle cell (VSMC) migration and proliferation contribute to intimal thick-
ening in vivo.1 Intimal thickening underlies complications, 
such as restenosis after angioplasty and stent implantation 
and late failure of vein grafts,2 and acts as the soil for ath-
erosclerosis.3 VSMC migration into the intima is a key pro-
cess in intimal thickening because if VSMCs do not enter 
the intima, there is no opportunity for accelerated VSMC 
proliferation within the intima. Currently, many approaches 
designed to reduce intimal thickening aim to retard VSMC 
proliferation, but antimigratory approaches may be equally 
desirable.
The Wnt signaling pathway has been implicated in inti-
mal thickening and VSMC migration and proliferation by 
both our own group4–6 and others.7–10 Abnormal upregula-
tion of the Wnt pathway in various disease states mimics 
the classic role of the Wnt pathway during embryonic devel-
opment, where the pathway controls cell migration and 
proliferation during the formation of tissues and organs.11 
The Wnt family consists of 19 highly conserved genes that 
encode secreted glycoproteins involved in cell signaling. 
The Wnt ligands bind to frizzled (Fzd) receptors and their 
coreceptors, the low-density lipoprotein–related proteins 
5/6, to activate downstream pathways.12 Upregulation of 
the Wnt pathway has been well established in many can-
cer subtypes13 and in the development of osteoarthritis14; 
however, their role in atherosclerosis and restenosis is less 
well established. Evidence shows that the Wnt pathway, via 
the receptor low-density lipoprotein–related protein 6, reg-
ulates cell proliferation and survival in VSMCs,7 whereas 
a Wnt pathway antagonist reduced proliferation.15 We pre-
viously demonstrated that Wnt4 directly induced VSMC 
proliferation and caused intimal thickening in vivo, via 
Fzd1 activation and cyclin D1 upregulation.5 Additionally, 
in this study, we demonstrated that although Wnt2 mRNA 
was significantly elevated in proliferating VSMCs, this 
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Objective—Increased vascular smooth muscle cell (VSMC) migration leads to intimal thickening in coronary artery restenosis 
and vein graft failure, as well as acts as a soil for atherosclerosis. Investigating factors involved in VSMC migration may 
enable us to reduce intimal thickening and improve patient outcomes. In this study, we determined whether Wnt proteins 
regulate VSMC migration and thereby intimal thickening.
Approach and Results—Wnt2 mRNA and protein expression were specifically increased in migrating mouse aortic 
VSMCs. Moreover, VSMC migration was induced by recombinant Wnt2 in vitro. Addition of recombinant Wnt2 protein 
increased Wnt1-inducible signaling pathway protein-1 (WISP-1) mRNA by ≈1.7-fold, via β-catenin/TCF signaling, 
whereas silencing RNA knockdown of Wnt-2 reduced WISP-1 mRNA by ≈65%. Treatment with rWISP-1 significantly 
increased VSMC migration by ≈1.5-fold, whereas WISP-1 silencing RNA knockdown reduced migration by ≈40%. 
Wnt2 and WISP-1 effects were integrin-dependent and not additive, indicating that Wnt2 promoted VSMC migration 
via WISP-1. Additionally, Wnt2 and WISP-1 were significantly increased and colocated in human coronary arteries 
with intimal thickening. Reduced Wnt2 and WISP-1 levels in mouse carotid arteries from Wnt2+/− and WISP-1−/− mice, 
respectively, significantly suppressed intimal thickening in response to carotid artery ligation. In contrast, elevation of 
plasma WISP-1 via an adenovirus encoding WISP-1 significantly increased intimal thickening by ≈1.5-fold compared 
with mice receiving control virus.
Conclusions—Upregulation of Wnt2 expression enhanced WISP-1 and promoted VSMC migration and thereby 
intimal thickening. As novel regulators of VSMC migration and intimal thickening, Wnt2 or WISP-1 may 
provide a potential therapy for restenosis and vein graft failure.  (Arterioscler Thromb Vasc Biol. 2016;36:00-00. 
 DOI: 10.1161/ATVBAHA.116.307626.)
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was not translated into protein, and recombinant Wnt2 
(rWnt2) protein did not increase VSMC proliferation in 
vitro.5 The Wnt pathway has also been shown to have a 
role in cell migration, with Wnt3a involvement in both 
migration and adhesion of VSMCs through ILK regula-
tion of β1-integrin.10 However, on initiation of this study, it 
was unclear which Wnt proteins modulated VSMC growth 
factor–induced migration and whether Wnt-induced VSMC 
migration promoted intimal thickening in vivo. Many genes 
are upregulated by the Wnt pathway, some of which are 
known to modulate VSMC migration, including Wnt-1-
inducible signaling pathway protein-1 (WISP-1/CCN4).16 
WISP-1 is a member of the CCN family of genes,17 which 
regulates fibrosis and wound healing,18 angiogenesis,19 
osteogenesis,20 and cancer.21 In cultured VSMCs, WISP-1 
promotes survival,19 proliferation,22 and migration through 
integrin α5β1.23
In this study, we aimed to identify whether any of the 19 
Wnts are involved in VSMC migration in vitro and thereby 
intimal thickening in vivo. In addition, if a candidate was con-
firmed, to investigate the downstream Wnt pathway targets 
that promote VSMC migration in vitro and intimal thickening 
in vivo.
Materials and Methods
Materials and Methods are available in the online-only Data 
supplement.
Nonstandard Abbreviations and Acronyms
Fzd frizzled receptor
rWnt2 recombinant Wnt2
SiRNA silencing RNA
VSMC vascular smooth muscle cell
WISP-1 Wnt-1-inducible signaling pathway protein-1
BA
C D
Figure 1. Wnt2 was upregulated in migrating smooth muscle cells in vitro. A, Wnt2 mRNA was quantified by oligonucleotide array, n=3, 
and quantitative polymerase chain reaction (QPCR), n=6. Data were normalized with standard housekeeping genes for the array and with 
18S for QPCR and then expressed as a fold change from control (unwounded/nonmigratory). * indicates a significant difference from con-
trol, P<0.05, 1-sample t test. B, Western blotting for Wnt2 protein in control and (C) migrating (wounded, W) smooth muscle cells normal-
ized with b-actin. * indicates a significant difference from control, P<0.05, 1-sample t test, n=4. C, Wounded vascular smooth muscle cells 
(VSMCs) were treated with recombinant Wnt2 protein or subjected to Wnt2 silencing with siRNA (Si) and the distance migrated measured. 
Controls were treated with Allstars siRNA controls. * indicates a significant difference from control, P<0.05, analysis of variance (ANOVA), 
and Student Newman Keul’s post test, n=4. D, Wnt2-induced migration of cells subjected to siRNA for Frizzled 1 and 6, expressed as a 
% of the Allstars siRNA control. * indicates a significant difference from control, P<0.05, 1-sample t test, n=3.
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Results
Wnt2 Was Upregulated in 
Migrating VSMCs In Vitro
Wnt mRNA levels during VSMC migration were assessed 
using an in vitro scratch wound assay with multiple wounds to 
stimulate migration of the VSMCs. mRNA was extracted from 
VSMCs and applied to a focussed Wnt pathway microarray to 
assess whether the level of expression changed during migra-
tion. A significant increase was only observed in Wnt2 mRNA 
(Figure 1A), and this change was confirmed using quantitative 
polymerase chain reaction (Figure 1A). No significant change 
was seen in the mRNA levels of any other Wnts (see Table 
III in the online-only Data Supplement). It was observed by 
Western blotting (Figure 1B) and immunocytochemistry 
(Figure I in the online-only Data Supplement) that the increase 
in Wnt2 mRNA was translated into augmented Wnt2 protein 
levels in migrating VSMCs. Migrating VSMCs on the wound 
edge could be seen to express higher levels of Wnt2 protein 
than nonmigratory VSMCs further away from the wound edge 
(Figure I in the online-only Data Supplement).
Wnt2 Promoted VSMC Migration In Vitro
Addition of rWnt2 protein significantly increased VSMC 
migration in vitro, whereas knockdown of Wnt2 using silenc-
ing RNA (siRNA) inhibited migration (Figure 1C). When 
rWnt2 was added back to VSMCs subjected to Wnt2 knock-
down, the inhibitory effect of Wnt2 siRNA was reversed 
(Figure 1C). rWnt2 also increased migration in the transwell 
assay (92.8±10.4 cells versus 47.3±5.8 in control, n=4; P<0.05 
student t test). We previously showed that Fzds 1 and 6 are the 
predominant Fzds expressed in VSMCs.5 Knockdown of Fzd6 
using siRNA resulted in a significant reduction in migration, 
whereas Fzd1 knockdown had no significant effect on migra-
tion (Figure 1D).
Wnt2 Was Upregulated During Intimal Thickening
To corroborate these in vitro changes in a relevant in vivo 
model of intimal thickening, mice were subjected to left 
carotid artery ligation. Carotids were removed after 28 days 
and stained for the presence of Wnt2 using immunofluores-
cence (Figure 2A–2C). Elevated levels of Wnt2 protein were 
detected in the media, and the intima of ligated carotids was 
compared with the unligated control arteries (autofluores-
cence from red blood cells was observed in the nonimmune 
immunoglobulin-negative controls and was excluded from 
analysis of Wnt2, only intimal fluorescence and not luminal 
fluorescence was measured).
Wnt2 Promoted Intimal Thickening In Vivo
To determine whether Wnt2 regulated intimal thickening in 
vivo, Wnt2+/− mice were subjected to left carotid artery liga-
tion. In unligated carotid arteries, Wnt2 protein was undetect-
able in both the Wnt2+/− and Wnt2+/+ mice (Figure IIA and IIB 
in the online-only Data Supplement). After carotid ligation, we 
observed reduced levels of Wnt2 protein in the ligated arter-
ies of Wnt2+/− mice using immunofluorescence on the carotid 
arteries (Figure IIC in the online-only Data Supplement), 
compared with ligated arteries of control wild-type (Figure 
IID in the online-only Data Supplement); the amount of stain-
ing was quantified, showing that the amount of Wnt2 protein 
within the intima was significantly reduced after 3 and 28 days 
of carotid ligation (Figure IIE and IIF in the online-only Data 
Supplement). This reduction in Wnt2 was associated with 
attenuated intimal thickening in the Wnt2+/− mice (Figure 2D). 
No significant difference was observed in the percentage of 
proliferating cells (measured using bromodeoxyuridine stain-
ing) at either 3 or 28 days (Figure III in the online-only Data 
Supplement) in either the intima (A) or the media (B).
Wnt2 Affected WISP-1 Levels, 
Both In Vitro and In Vivo
Treatment of VSMCs with rWnt2 induced WISP-1 mRNA, 
whereas Wnt2 knockdown using siRNA resulted in a down-
regulation of WISP-1 mRNA quantified with quantitative 
polymerase chain reaction (Figure 3A). However, treatment 
of VSMCs with rWnt4 did not induce WISP-1 mRNA (1± ver-
sus 0.93±0.05). Treatment with rWnt2 caused no significant 
change in any other downstream Wnt/β-catenin downstream 
targets that we analyzed (see Table IV in the online-only 
Data Supplement). Induction of WISP-1 by Wnt2 treatment 
was inhibited using the β-catenin inhibitor CCT03134-
hydrobromide (Figure 3B). Knockdown of WISP-1 led to a 
significant reduction in migration in vitro, which was of a sim-
ilar extent to that seen with knockdown of Wnt2 (Figure 3C). 
Simultaneous knockdown of both Wnt2 and WISP-1 did not 
produce an additive effect, suggesting that WISP-1 and Wnt2 
are working in series rather than in parallel, with most likely 
WISP-1 downstream of Wnt2. Levels of Wnt2 and WISP-1 
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Figure 2. Wnt2 promoted intimal thickening. Immunofluores-
cence for Wnt2 protein in carotid arteries 28 days after ligation 
and control unligated control arteries. A, Ligated left carotid 
artery with intimal thickening at 28 days after ligation. B, Unli-
gated control carotid artery. C, Nonimmune IgG negative control 
(ligated artery). Wnt2 protein (green) and nuclei blue (DAPI). Red 
dotted line indicates the intimal:medial boundary. D, Intima area 
in wild-type (Wnt2+/+) and Wnt2 heterozygous knockout mice 
(Wnt2+/−), * indicates P<0.05, t test, n=14 per group. Images are 
EVG staining for elastin in longitudinal sections. Scale bar repre-
sents 50 μm in A, B, and C and 100 μm in D.
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also appeared to be related in vivo, where levels of WISP-1 
were significantly reduced in the intimal lesions of Wnt2+/− 
mice compared with the wild-type controls (Figure 3D).
Wnt2 Induced WISP-1 via β-Catenin
Migration of cells in response to rWnt2, but not rWISP-
1, was inhibited by the β-catenin inhibitor, CCT03134-
hydrobromide (Figure 3E and 3F). This indicated that Wnt2 
acts via β-catenin in migrating cells but that WISP-1-induced 
migration is β-catenin-independent.
Wnt2 and WISP-1 Both Required Integrins
Cell migration in response to both rWnt2 (Figure 3E) and 
rWISP-1 (Figure 3F) and wounding were both inhibited 
by the integrin inhibitor, RGD peptide, but not by a control 
peptide, suggesting that integrins are downstream of both 
Wnt2 and WISP-1.
Wnt2 and WISP-1 Colocated 
Within Intimal Thickenings
To investigate the association of Wnt2 with WISP-1, we exam-
ined whether these proteins were colocated in mouse-ligated 
carotid arteries (Figure 4A–4D; Figure V in the online-only 
Data Supplement) and early neointimal thickenings (without 
foam cells and plaque formation) in human coronary arteries 
(Figure 4E and 4F) by staining for Wnt2 and WISP-1 using 
immunofluorescence. We observed that Wnt2 and WISP-1 
proteins were indeed colocated in both mouse and human 
arteries during intimal thickening. In human coronary arteries, 
the amount of Wnt2 and WISP-1 proteins were significantly 
A B
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Figure 3. Wnt1-inducible signaling pathway protein-1 (WISP-1) was induced by Wnt2 and WISP-1-promoted cell migration. A, Relative 
expression of WISP-1 mRNA in vascular smooth muscle cells (VSMCs) with and without Wnt2 protein treatment, n=4, and after silencing 
of Wnt2 with siRNA (Si), n=5. B, WISP-1 mRNA after treatment with rWnt2 and CCT, n=3. C, Migration of VSMCs after silencing Wnt2 and 
WISP-1 using scratch wound assay, n=5. D, The percentage of WISP-1-positive intimal cells in wild-type (Wnt2+/+) and Wnt2+/− mouse 
carotid arteries 28 days after ligation, n=7. Migration of cells after treatment with either rWnt2 (E) or rWISP-1 (F), with or without CCT or 
RGD peptide or control peptide, n=4. * indicates significant difference vs control, P<0.05. $ indicates significant difference from rWnt2/
rWISP-1 treatment, using either t test or analysis of variance (ANOVA) as applicable.
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higher in arteries with early intimal thickenings compared 
with normal control undiseased arteries (Figure 4G). In addi-
tion, there was a significant correlation between the amount 
of Wnt2 and WISP-1 proteins in the vessels (r=0.647 and 
r2=0.419, n=13; P<0.05 and P<0.02). There was no sig-
nificant difference in expression of either Wnt2 or WISP-1 
between the intima and the media.
WISP-1 Promoted Intimal Thickening In Vivo
Deficiency of the WISP-1 gene produced a significant reduc-
tion in the intima formation (Figure 5A). In contrast, using 
an adenovirus encoding WISP-1 protein, we increased plasma 
levels of WISP-1 protein at 3 and 7 days post infection (Figure 
IV in the online-only Data Supplement), and this resulted in a 
significant increase in intimal formation in the carotid artery 
after ligation (Figure 5B). This confirmed that WISP-1 pro-
moted intimal thickening in the mouse in vivo. Sections were 
stained with ISEL to identify apoptotic cells. Half of all sec-
tions examined had no apoptosis, whereas others had 1 or 2 
apoptotic cells. No significant difference was seen in apopto-
sis rates between the control and WISP-1-deficient mice (data 
not shown). The percentage of proliferating cells (measured 
by PCNA) was significantly reduced in the vessels of WISP-
1-deficient animals compared with the wild-type controls in 
both the media and the intima of the vessels (Figure 5C).
Discussion
This study demonstrates that Wnt2 and WISP-1 are upregu-
lated in migrating VSMCs in vitro and in intimal cells in 
vivo. We have also shown that modulating the levels of either 
Wnt2 or WISP-1 directly affects VSMC migration in vitro 
and intimal thickening in vivo. We have shown that Wnt2 
upregulates WISP-1 and promotes VSMC migration, via 
β-catenin-dependent signaling. Additionally, we demonstrated 
that WISP-1 and Wnt2 promote VSMC migration via interac-
tion with integrins. Consequently, we suggest that Wnt2 and 
WISP-1 are novel regulators of intimal thickening and, thereby, 
potential targets for reducing intimal thickening in patients 
after coronary artery bypass grafts and stent implantation.
Although this is the first study to demonstrate the involve-
ment of Wnt2 in adult VSMC migration and intimal thick-
ening in vivo, Wnt2 does have a well-characterized role in 
cell migration in other scenarios such as during embryonic 
development; for example, mouse embryo VSMCs also 
express Wnt2 as they migrate to form the heart, vasculature, 
and lungs.24 Wnt2 also has a role in cell migration in various 
cancers. Wnt2 levels were linked to metastasis in pancreatic 
cancer,25 whereas inhibition of Wnt2 in mouse nonsmall cell 
lung cancer cells resulted in reduced tumor cell growth.26 In 
scleroderma patients, Wnt2 was found to be elevated and asso-
ciated with activation of β-catenin,27 as we have shown in our 
study. Therefore, it is possible that the disease states of intimal 
thickening or cancers lead to a reawakening of this embryonic 
pathway, which is usually quiescent in mature cells, leading to 
Wnt2-dependent migration of cells.
Other members of the Wnt family have also been impli-
cated in intimal thickening, both by our own group and oth-
ers. For example, Wu et al10 reported that Wnt3a stimulated 
migration, adhesion, and proliferation of rat VSMCs in cul-
ture. Previous work in our group using a similar approach to 
this study showed that Wnt4 was increased during VSMC 
proliferation and that modulation of Wnt4 led to changes 
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Figure 4. Colocation of Wnt2 and Wnt1-inducible signaling pathway protein-1 (WISP-1) in mouse intimal lesions and human coronary 
artery disease. Immunofluorescence for Wnt2 (A: green) and WISP-1 (B: red) proteins and merged images (C: yellow). Nonimmune IgG-
negative control (D). White dotted line indicates the intima:media boundary. Scale bar in A represents 50 μm and applies to panels A–D. 
Human early coronary lesions were subjected to immunofluorescence for Wnt2 protein (E: green) and WISP-1 protein (F: red), nuclei are 
blue (DAPI) in human coronary artery with intima. Scale bar in E represents 50 μm and applies to panels E and F. Quantification of inti-
mal and medial Wnt2 and WISP-1 proteins in control undiseased coronary arteries and coronary arteries with early intimal thickening (G). 
* indicates significant difference from controls (analysis of variance [ANOVA] and Kruskal Wallis post test, n=5 controls, n=5 with intimal 
thickening; P<0.05).
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in cell proliferation and intimal thickening.5 Moreover, we 
demonstrated that although Wnt2 mRNA, as well as Wnt4 
mRNA, was increased in proliferating cells, this only trans-
lated into an increase in protein expression for Wnt4, and not 
for Wnt2. We also tested addition of both rWnt2 and rWnt4 
proteins to VSMCs in culture to assess whether they could 
directly affect proliferation. We observed that only Wnt4 
induced VSMC proliferation and Wnt2 had no significant 
effect on proliferation. Additionally, in our previous study, 
we demonstrated that Wnt4 protein levels were induced 
during intimal thickening in vivo, and intimal thickening 
induced by carotid artery ligation was significantly reduced 
in Wnt4+/− mice. A comparison of these 2 studies in our group 
is summarized in Figure 6 and suggests that regulation of 
VSMC migration and proliferation via β-catenin-dependant 
signaling are controlled by different Wnt protein members, 
with Wnt2 controlling migration predominantly via Fzd6 
(although the involvement of Fzd1 cannot be ruled out) and 
Wnt4 promoting proliferation via Fzd1.
We investigated the mechanism of action and discovered 
that Wnt2 promoted migration via the β-catenin-dependent 
canonical signaling pathway, which increased WISP-1 levels. 
Knockdown of either Wnt2 or WISP-1 in vitro using siRNA 
resulted in a similar reduction in cell migration. However, 
when both were added, this offered no increase in effect. This 
suggested that they were acting in series rather than in paral-
lel. To investigate this further, we looked at the effect of add-
ing rWnt2 and found that this significantly increased the levels 
of WISP-1 in vitro, in contrast to Wnt4 which did not affect 
WISP-1 levels. We also showed that WISP-1 was reduced in 
Wnt2 knockout mouse–ligated carotids in vivo. This shows 
that WISP-1 can be regulated directly by Wnt2, and so WISP-1 
is most likely to be downstream of Wnt2. Wnt2 and WISP-1 
were also found to be colocated in ligated mouse carotid arter-
ies, confirming that activation of WISP-1 by Wnt2 is physi-
ologically relevant because WISP-1 is found alongside Wnt2.
WISP-1 has been shown previously by our own group19 
to be important in VSMC survival and by Liu et al23 to pro-
mote both VSMC migration and proliferation in cultured rat 
VSMCs. Marchand et al confirmed the presence of WISP-1 in 
human mammary arterial cells,28 whereas Reddy et al22 showed 
than in human VSMCs, interleukin-18 increased survival and 
proliferation, via TCF/LEF and WISP-1. WISP-1 then acted 
via AP-1 to upregulate MMP-2, -9 and -14 mRNA. Our study 
therefore corroborates the findings of Liu et al,23 showing 
similar mechanisms in both rat and mouse VSMCs in culture; 
however, we do not see the upregulation of MMP-2, -9, and 
-14 by WISP-1. This is the first study to show that WISP-1 
leads to intimal thickening in vivo and the first to examine the 
mechanism of action. The interplay between Wnt5a and Wnt2, 
which are both able to act via β-catenin to activate WISP-1 
(Figure 6), reveals the complexity of how various Wnts may 
act synergistically by overlapping pathways to produce differ-
ent effects. More work is needed in this area to define exactly 
how these pathways may act either separately or together in 
different disease models.
As with Wnt2, WISP-1 has been studied in cancer cells, 
where it has been shown to be a chemoattractant,20 encour-
age metastasis,29 increase invasiveness, and decrease chances 
of survival.30–32 WISP-1 has also been shown in human can-
cer cells to be upregulated compared with healthy cells33 and 
to stimulate migration via NFκB activation of MMP-2. Our 
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Figure 5. Wnt1-inducible signaling pathway pro-
tein-1 (WISP-1) promoted intimal thickening.  
A, Intima area within carotid arteries 28 days after 
ligation in wild-type controls and WISP-1−/− mice, 
n=12. B, Intima area within carotid arteries 28 
days after ligation in mice infected with control 
adenovirus and adenovirus to overexpress WISP-
1, n=10. Scale bars represents 100 μm. * indi-
cates significant difference vs control, P<0.05.  
C, Percentage of proliferating cells in the intima 
and media measured by PCNA staining. * indi-
cates significant difference vs control, P<0.05.
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study shows that Wnt2 acts via β-catenin to upregulate WISP-
1, which then acts through integrins to increase cell migration. 
This confirms that a similar pathway is utilized by WISP-1 
in VSMCs as in other cell types. For example, in human oral 
squamous cell carcinoma cells, WISP-1 acts through AP-1 
and the αvβ3 integrin receptor,30 whereas in osteogenesis, 
WISP-1 acts via α5β1 integrin.20
To establish whether this Wnt2-WISP-1 association was 
present in human intimal lesions as well as in mice, we stained 
sections from human coronary arteries with early-stage inti-
mal thickening (without atherosclerotic plaques) to locate 
Wnt2 and WISP-1. We found that Wnt2 and WISP-1 was 
colocated and increased in diseased coronary vessels com-
pared with control vessels, and the increase in the levels of 
Wnt2 and WISP-1 in diseased vessels were correlated. This 
suggested that as Wnt2 increased, this led to an associated 
increase in WISP-1 as we observed in vitro.
In summary, we have found that Wnt2 is upregulated in 
migrating cells both in vitro and in vivo and that Wnt2 pro-
moted VSMC migration in vitro and intimal thickening in 
vivo. We identified that downstream, Wnt2 activates β-catenin, 
leading to an upregulation of WISP-1, which like Wnt2 also 
has the ability to stimulate migration of cells in vitro and inti-
mal thickening in vivo, via integrins. Although both Wnt2 and 
WISP-1 have been separately implicated to be involved in 
cell migration in other cell types, the action of Wnt2 promot-
ing migration via WISP-1 had not been previously reported. 
WISP-1 may provide a more suitable target for drug interven-
tion compared with Wnt2 because the effects may be more 
specific further downstream in the pathway, and as we have 
shown WISP-1 promotes both migration and proliferation in 
this model, so could be a preferable candidate. However, as 
noted previously, WISP-1 affects other cell types; so ideally, 
a tissue-targeted WISP-1 inhibitor would be preferable, such 
as stent coating or ex vivo vein graft application before bypass 
surgery. Targeting migration and proliferation of VSMCs from 
the media of the vessel into the intima should retard the for-
mation of a neointima after therapies, such as coronary artery 
bypass grafts and stent implantation, and therefore increase 
the longevity of these treatments.
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•	 Wnt2	is	upregulated	in	migrating	cells,	and	it	promoted	vascular	smooth	muscle	cell	migration	in	vitro	and	intimal	thickening	in	vivo.
•	 Wnt2-induced	migration	 is	dependent	 on	β-catenin	activation,	 leading	 to	an	upregulation	of	Wnt1-inducible	 signaling	pathway	protein-1,	
which	in	turn	promoted	vascular	smooth	muscle	cell	migration	via	integrins.
•	 Wnt1-inducible	signaling	pathway	protein-1	promoted	intimal	thickening	in	vivo.
•	 This	is	the	first	demonstration	that	Wnt2	promoted	migration	via	Wnt1-inducible	signaling	pathway	protein-1.
•	 Wnt1-inducible	signaling	pathway	protein-1	may	be	a	suitable	target	for	reducing	intimal	thickening	after	therapies	such	as	coronary	artery	
bypass	grafts	and	stent	implantation	and,	therefore,	increase	the	longevity	of	these	treatments.
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Materials and Methods 
Animals 
The housing and care of all the animals and the procedures used in these studies 
were performed in accordance with the guidelines and regulations of the University of 
Bristol and the United Kingdom Home Office. The investigation conforms to the Guide 
for the Care and Use of Laboratory Animals published by the US National Institutes of Health 
(NIH Publication No. 85-23, revised 1996). 
Transgenic mice. Wnt2 heterozygous knockout mice (Wnt2+/-) on a pure CD-1 
background from more than 10 backcrosses, were kindly provided by Dr Richard Lang 
(Cincinnati Children’s Hospital, Cincinnati, OH). WISP-1 homozygous knockout mice 
(WISP-1-/-) on a pure C57/bl6J background from more than 10 backcrosses, were 
kindly provided by Dr Marian Young (NIH, Bethesda, Maryland). Mice were bred within 
the University of Bristol animal unit to provide sufficient numbers of male Wnt2+/- or 
WISP-1-/- mice and their wild type littermate controls (Wnt2+/+ or WISP-1+/+). 
Homozygous Wnt2-/- animals could not be used as a result of perinatal death due to 
placental defects 1. 
Elevation of plasma WISP-1. To overexpress WISP-1, 30 mice were anaesthetised 
using inhaled isoflurane and warmed on a heated plate, to increase the prominence 
of the tail vein, before receiving a tail vein injection of RAd66 empty virus (8 x 1010 
particles/mouse1.1 x 109 pfu/mouse) as previously described 2-4. Mice were allowed 
to recover on a heat mat before returning them to their cage. Four hours later the 
procedure was repeated and mice were given a further injection of either RAd66 or 
RAdWISP-1 (15 mice in each group, 2.2 x 108 pfu/mouse). The RAdWISP-1 encoding 
virus was kindly supplied by Marian Young and was previously described 5. 
Carotid ligation. Left carotid artery ligations were performed to induce intimal 
thickening, as described previously 6. Thirty mice were anaesthetised using inhaled 
isoflurane with oxygen and intraperitoneal injection of buprenorphine hydrochloride 
(1.5mg) and prepared for sterile surgery. The left common carotid artery was dissected 
and ligated just proximal to the carotid bifurcation to induce intimal formation. Mice 
also received an implanted minipump (Alzet 2004) in the subcutaneous space on their 
back containing BrdU (25mg/ml) to enable identification of proliferating cells. 
Histochemistry, Immunohistochemistry and Immunofluorescence 
Carotid arteries were removed either 3 or 21 days following ligation surgery, formalin 
fixed for 24 hours and embedded longitudinally or transversely in agar before 
processing and embedding in paraffin wax. 3 mm sections were cut onto Superfrost 
slides for elastin van Gieson (EVG) staining and on to Superfrost Plus slides for 
immunohistochemistry and immunofluorescence. EVG stained sections were used for 
visualisation and measurement of the vessel and lesion by image analysis (Image 
Pro). Immunohistochemistry was performed to visualise BrdU incorporation (Sigma: 
B2531; 8.6mg/ml) and PCNA staining (Abcam 18197; 1mg/ml); and 
immunofluorescence was utilised to localise Wnt2 (Santa Cruz: SC5208; 1.25mg/ml), 
WISP-1 (R&D: AF1680; 1mg/ml), and cleaved caspase 3 (R&D Systems: MAB835; 
10mg/ml). Non-immune IgG of the same species as the primary was used as negative 
control in all protocols at the same concentration as the primary antibody to 
demonstrate the specificity of the protocol. Apoptosis was measured using ISEL as 
described previously 7. To investigate the association of Wnt2 with WISP-1 during 
intimal thickening in humans, we examined whether these proteins were co-located 
in  early neointimal thickenings (without foam cells and plaque formation) in human 
coronary arteries by staining for Wnt2 and WISP-1 using 
immunofluorescence. Human right coronary arteries were removed from hearts 
collected for valve retrieval from deceased donors (Local ethical approval 
REC#08/H0107/48). 
Tissue culture and in vitro migration assays 
Primary cultured VSMCs were obtained by culturing explants from aortae from C57/bl6 
mice as described previously 6. Cells were used from passage 3-9 and at least 3 
different preparations were used for each experiment. VSMCs were quiesced for 24 
hours at 37oC and 5% CO2 in serum free medium (SFM) before either treatment with 
500ng/ml recombinant Wnt2 or being subjected to either a single or multiple scratch 
wound assay as described previously 8, in SFM supplemented with 20ng/ml PDGF 
and 2mM hydroxyurea (to inhibit proliferation). To quantify migration, VSMCs were 
grown in a 24 well plate and subjected to two perpendicular wounds to form a cross. 
Wells were photographed immediately following wounding and then again 24 hours 
after wounding to measure the distance migrated by the VSMCs. For measurement of 
mRNA or protein, VSMCs were cultured in a 6 well plate and subjected to 20 wounds 
in two directions to form a grid pattern. VSMCs were left to migrate for either 6 hours 
(for mRNA) or 24 hours (for protein) before lysing the VSMCs in the relevant lysis 
buffer. In some experiments VSMCs were cultured in the presence of 500 ng/ml 
recombinant Wnt2, or recombinant WISP-1 and the inhibitors CCT03134-
hydrobromide (Tocris, 20nM) and RGD peptide (Peptides International, 250mM) were 
also added. Cells were also seeded into a transwell cell culture inserts with 8mm pores 
(Millipore) and the number of VSMCs that migrated across the membrane in response 
to Wnt2 after 24 hours was measured as previously described 8. 
RNA extraction and reverse transcription 
RNA was extracted from VSMCs using the RNAeasy kit (Qiagen) according to the 
manufacturer’s instructions. RNA was then processed for Q-PCR analysis using 
reverse transcription using the RT-PCR Kit (Qiagen) or for focussed microarray 
analysis as described below. 
Focussed Microarray Analysis 
RNA was directly labelled with Biotin-UTP (Roche) and amplified using the TrueLabel 
AMP 2.0 Kit (SuperArray: GA-030). The Biotin-UTP labelled RNA was cleaned using 
the RNAeasy kit (Qiagen). A mouse Wnt pathway microarray (SuperArray: OMM-043-
4) was left rotating overnight at 37oC in a hybridising oven with 1mg of cleaned, purified 
and labelled mRNA in 2ml of hybridisation solution. Hybridised oligonucleotides were 
detected using an enhanced luminescence kit (SuperArray: D-01,) according to the 
instructions, after washing twice for 30 minutes with SSC containing buffers (Sigma: 
85635) at room temperature. The GEAnalysis software (SuperArray: GA-021) was 
used for quantification following normalisation using housekeeping genes and 
concentration controls (GAPDH, BAS2C, Ppia, Hspcb, B2m, Rps27a, and two blank 
controls) on the array. 
Quantitative PCR (Q-PCR) 
cDNA was subjected to Q-PCR for Wnt pathway genes using specific primers (see 
Supplementary Table I) as described previously 6. Results were normalised to 18s 
ribosomal RNA. 
 
Western Blotting 
SDS lysis buffer was used to extract VSMC proteins and total protein concentration 
was measured using a bicinchroninic acid protein assay kit (Pierce). Equal protein 
concentrations were loaded on 4-12% gradient gels (Novex Bis-Tris gel) and 
transferred on to 0.2mm nitrocellulose membranes. Blots were blocked with 5% (w/v) 
skimmed milk powder and incubated overnight at 4oC with anti-Wnt2 antibody (Abcam: 
ab27794; 4mg/ml) diluted in starting block (Pierce). Primary antibodies were detected 
using HRP conjugated secondary antibodies and enhanced chemiluminescence 
reagent (ECL, Amersham). Optical density of bands was quantified using densitometry 
(Quantity One) and normalised to a b-actin loading control (Sigma: A5316; 110ng/ml). 
Immunocytochemistry 
Following the in vitro migration assay VSMCs were fixed in 3% (w/v) 
paraformaldehyde for 10 minutes, washed with 0.1% (v/v) triton in PBS and blocked 
with 20% (v/v) rabbit serum for 1 hour. VSMCs were then and treated with Wnt2 
antibody (Santa Cruz: SC5208; 5mg/ml) or IgG used at 200 mg/ml in 1% (w/v) BSA in 
PBS overnight at 4°C. The next day VSMCs were washed and treated with rabbit anti 
goat Alexa flour 488 at 1:200 for 45 minutes, wrapped in foil before washing and 
mounting with Prolong gold with 4',6-diamidino-2-phenylindole (DAPI). 
Silencing RNA (SiRNA) 
SiRNA oligonucleotides for Wnt2, WISP-1 and Frizzleds 1 and 6 (Supplementary 
Table II) were purchased from Qiagen along with Allstars scrambled negative control 
(Qiagen SI03650318) and introduced into VSMCs using an AMAXA nucleofector 
device and VSMC kit (API-1004, Lonza) according to the manufacturer’s instructions. 
VSMCs (1 x 106) were subjected to nucleofection with 250pmol of Wnt2, WISP-1, Fzds 
or Allstars control siRNAs using program A33 and analysed after 24 hours. The 
knockdown efficiency was quantified using Q-PCR of target mRNA and found to be 
significantly reduced by <50%, as previously published for Wnt2 6, WISP-1 9 and Fzds 
6
. 
Statistics 
 
Results are expressed as mean+SEM. All data was checked for normal distribution 
and since this was the case for all data, they were analysed by student t-test for 
comparison of two groups, one-sample t-test for one group analyses and two-way 
ANOVA with Kruskal Wallis post-test for multiple comparisons with more than two 
groups. A significant difference was accepted when p<0.05. 
 
  
References 
1. Sousa KM, Villaescusa JC, Cajanek L, Ondr JK, Castelo-Branco G, Hofstra 
W, Bryja V, Palmberg C, Bergman T, Wainwright B, Lang RA, Arenas E. Wnt2 
regulates progenitor proliferation in the developing ventral midbrain. J Biol 
Chem. 2010;285:7246-7253 
2. Lyon C, Johnson J, White S, Sala-Newby G, George S. Ec4, a truncation of 
soluble n-cadherin reduces vascular smooth muscle cell apoptosis and 
markers of atherosclerotic plaque instability. Mol Ther - Meth Clin Develop. 
2014;1:doi:10.1038/mtm.2014.1034 
3. Lyon CA, Johnson JL, Williams H, Sala-Newby GB, George SJ. Soluble n-
cadherin over-expression reduces features of atherosclerotic plaque 
instability. Arterioscler Thromb Vasc Biol. 2009;29:195-201 
4. Johnson JL, Baker AH, Oka K, Chan L, Newby AC, Jackson CL, George SJ. 
Suppression of atherosclerotic plaque progression and instability by tissue 
inhibitor of metalloproteinase-2: Involvement of macrophage migration and 
apoptosis. Circulation. 2006;113:2435-2444 
5. Ono M, Inkson CA, Kilts TM, Young MF. Wisp-1/ccn4 regulates osteogenesis 
by enhancing bmp-2 activity. Journal of Bone and Mineral Research. 
2011;26:193-208 
6. Tsaousi A, Williams H, Lyon C, Taylor V, Swain A, Johnson J, George S. 
Wnt4/b-catenin signalling induces vsmc proliferation and is associated with 
intimal thickening. Circ Res. 2011;108:427-436 
7. George SJ, Angelini GD, Capogrossi MC, Baker AH. Wild type p53 gene 
transfer inhibits neointima formation in human saphenous vein by modulation 
of smooth muscle cell migration and induction of apoptosis. Gene Ther. 
2001;8:668-676 
8. Dwivedi A, Sala-Newby GB, Newby AC, George SJ. Integrin-linked kinase is 
increased in intimal thickening and modulates cell-matrix and cell-cell 
interactions. Eur Heart J. 2004;25:748 
9. Mill C, Williams H, Monk B, Jeremy J, Johnson J, George S. Wnt5a signalling 
promotes survival via wisp-1. Arterioscler Thromb Vasc Biol. 2014;34:2449-
2456 
 
Supplementary Figure I: 
Wnt2 was increased in migrating smooth muscle cells in vitro.
Immunofluorescence for Wnt2 protein (green) in VSMCs 24 hours after subjecting to wound injury 
(A). Red line indicates the position of the wound.
(B) Migrating cells on edge of wound, (C) Non-migratory cells, (D) Non-immune IgG negative control. 
Nuclei are blue (DAPI). Scale bar represents 200 mm in (A) and 20 µm in (B) and applies to panels 
B-D.
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Supplementary Figure II: 
Wnt2 protein was reduced in Wnt2+/- mice.
Immunofluorescence for Wnt2 protein in control non-ligated carotid arteries (A and B) and ligated 
carotid arteries (C and D) 28 days following ligation. Wnt2+/- (A and C) and wild type mice (B and D: 
Wnt2+/+) dotted lines show the intima/media boundaries, i = intima, m = media. 
Quantification of Wnt2 protein in media of ligated carotid arteries after 3 days (E) and in intima and 
media after 28 days (F) in Wnt2+/- and control Wnt2+/+ mice, n=5, p<0.05 using t-test and Mann-
Whitney test. Scale bar = 50 mm.
0
2
4
6
8
10
12
14
Wnt2+/+ Wnt2+/-
%
 W
n
t2
 
po
si
tiv
e 
ce
lls
3 daysE
0
5
10
15
20
25
30
35
40
45
Wnt2+/+ Wnt2+/-
%
 W
n
t2
 
po
si
tiv
e 
ce
lls
28 daysF
C: Wnt2+/- D: Wnt2+/+
*
*
i
i
m
m
A: Wnt2+/- B: Wnt2+/+
Supplementary Figure III: 
Proliferation in ligated arteries.
The percentage of proliferating cells in the intima (A)  and media (B) was quantified by BrdU
incorporation and compared in Wnt2+/+ and Wnt2+/- mice at 3 days and 28 days after ligation, n=6.
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Supplementary Figure IV: 
Treatment with WISP-1 virus increased plasma WISP-1.
Plasma WISP-1 was quantified after 3, 7 and 28 days using ELISA.  
* indicates a significant difference from control (n=4, p<0.05, Mann-Whitney test).
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Supplementary Figure V: 
Wnt2 and WISP-1 are upregulated at 7 days
Representative images of immunofluorescence for Wnt2 (A) and WISP-1 (C) proteins 
(green) in serial sections of carotid arteries 7 days after ligation. Non-immune 
immunoglobulin controls are shown in (B) and (D), respectively. Nuclei are stained blue with 
DAPI.
Gene Source Primer sequence Forward Primer sequence Reverse
Brachyury Sigma GCTTCAAGGAGCTAACTAACGAG CCAGCAAGAAAGAGTACATGGC
Frizzled 7 Sigma GTCCCACCGCCTACCCTACTG GTGAGCACCGTGAAGAGCGTC
Frizzled 10 Sigma TGGTACGCATAGGGGTCTTC TCAGGCAGTCAGGTGTCTTG
FoxN1 Sigma CACTGGAAGCCTTTGAGGAG AAGGCAGGCTGAGAAGAACA
MMP2 Sigma GGCTGACATCATGATCAACTTTGG GCCATCAGCGTTCCCATACTTTAC
MMP7 Sigma AATGGCATTCCAGAATTGTCACCT GATCTCTCCTTGCGAAGCCAATTA
MMP9 Sigma GAGAACACCACCGAGCTATCCACT AGAGAGGAGTCTGGGGTCTGGTTT
MMP14 Sigma ACCACAAGGACTTTGCCTCTGAAG CACTGAGCTGTGAGATTCCCTTGA
Porcupine Sigma TGGAGTTCATGGGCTACCTCT CGTTTCTTGTTGCGAAGGAGT
Sox17 Sigma GATGCGGGATACGCCAGTG CCACCACCTCGCCTTTCAC
Senp2 Sigma GCTGGCTAAGGTTCTCGGC CTGGGATCTCATCAGTGTCCA
WISP-1 Sigma CGTGGAGCAACGGTATGAG GAGAGTGAAGTTCGTGGCC
WISP-2 Qiagen Quantitect QT01061571 
Supplementary Tables 
Supplementary Table I: Primer sequences used for Q-PCR
Gene Source Catalogue No Catalogue No
WISP-1 (Mouse) Qiagen S100212702 S102673370
Wnt2 (mouse) Qiagen S101472653 S101472660
Frizzled 1 Qiagen S100218771 S102674252 
Frizzled 6 Qiagen S102666979 S102708510
Supplementary Table II: SiRNA probes used for knockdown of WISP-1 and Wnt2
Wnt pathway member Average fold change 
(n=3 arrays)
One sample t-test vs. 1
p value
Wnt1 2.01±0.63 NS
Wnt2 2.39±0.35 p<0.05
Wnt2b 2.36±1.09 NS
Wnt3 0.64±1.10 NS
Wnt3a 0.05±0.98 NS
Wnt4 0.45±0.54 NS
Wnt5a 0.32±0.23 NS
Wnt5b 1.20±0.78 NS
Wnt6 1.28±0.34 NS
Wnt7a 0.40±0.39 NS
Wnt7b 1.50±1.22 NS
Wnt8a 1.45±0.96 NS
Wnt8b 2.88±1.86 NS
Wnt9a not detectable
Wnt9b 5.34±3.36 NS
Wnt10a 0.12±0.55 NS
Wnt10b 1.11±0.28 NS
Wnt11 1.46±0.67 NS
Wnt16 0.96±0.42 NS
Supplementary Table III: Fold change of Wnt pathway genes quantified by microarrays.
Wnt2 downstream 
target
Average fold change ± sem 
(n=3-6)
One sample t-test vs. 1
Brachyury 1.19±0.52 NS
Frizzled 7 2.52±1.46 NS
Frizzled 10 1.25±0.60 NS
MMP2 9.79±9.47 NS
MMP7 3.43±1.75 NS
MMP9 1.35±0.52 NS
MMP14 4.45±2.20 NS
Porcupine 1.21±0.33 NS
Senp2 1.22±0.32 NS
Sox17 1.32±0.36 NS
WISP-1 1.67±0.14 *P<0.05
WISP-2 0.79±0.57 NS
Supplementary Table IV: Fold change of potential Wnt2 responsive downstream genes
following addition of recombinant Wnt2: mRNA quantified by Q-PCR.
Arterial Injury
Wnt2
b-catenin/TCF
Fzd
VSMC 
MIGRATION
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